Home >> Healthcare >> Food & Beverage >>

Global Myelodysplastic Syndrome (MDS) Treatment Market by Manufacturers, Regions, Type and Application, Forecast to 2023

Published: Aug-2018 | Format: PDF | Global Info Research | Number of pages: 136 | Code: MRS - 355396

Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more often in older men than women. This syndrome is characterized by certain chromosomal mutations in Janus Kinase gene which include deletion of q arm in one or more chromosomes and complete deletion of chromosome 5 or 7 and an extra copy of chromosome 8.



Scope of the Report:

This report focuses on the Myelodysplastic Syndrome (MDS) Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

According to the American Cancer Society, the incidence rate for myelodysplastic syndrome is 13,000 new cases each year which happens at a rate of 4.8 cases per 100,000 people. This trend is heavily affected or rather influenced by the average age of the population which, according to the World Health Organization (WHO), is increasing and is expected to double from 12% to 22% between 2015 and 2050.

The worldwide market for Myelodysplastic Syndrome (MDS) Treatment is expected to grow at a CAGR of roughly 12.8% over the next five years, will reach 4560 million US$ in 2023, from 2210 million US$ in 2017, according to a new GIR (Global Info Research) study.



Market Segment by Manufacturers, this report covers

    Novartis AG

    Celgene Corporation

    Otsuka Pharmaceutical Co., Ltd

    Sandoz Inc

    Dr Reddys Laboratories Limited

    Pharmascience Inc

    Accord Healthcare Ltd

    Mylan N.V.



Market Segment by Regions, regional analysis covers

    North America (United States, Canada and Mexico)

    Europe (Germany, France, UK, Russia and Italy)

    Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

    South America (Brazil, Argentina, Colombia etc.)

    Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)



Market Segment by Type, covers

    Azacitidine

    Lenalidomide

    Decitabine

    Deferasirox



Market Segment by Applications, can be divided into

    Refractory cytopenia with unilineage dysplasia

    Refractory anemia with ringed sideroblasts

    Others



There are 15 Chapters to deeply display the global Myelodysplastic Syndrome (MDS) Treatment market.

Chapter 1, to describe Myelodysplastic Syndrome (MDS) Treatment Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Myelodysplastic Syndrome (MDS) Treatment, with sales, revenue, and price of Myelodysplastic Syndrome (MDS) Treatment, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Myelodysplastic Syndrome (MDS) Treatment, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Myelodysplastic Syndrome (MDS) Treatment market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Myelodysplastic Syndrome (MDS) Treatment sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Table of Contents



1 Market Overview

    1.1 Myelodysplastic Syndrome (MDS) Treatment Introduction

    1.2 Market Analysis by Type

        1.2.1 Azacitidine

        1.2.2 Lenalidomide

        1.2.3 Decitabine

        1.2.4 Deferasirox

    1.3 Market Analysis by Applications

        1.3.1 Refractory cytopenia with unilineage dysplasia

        1.3.2 Refractory anemia with ringed sideroblasts

        1.3.3 Others

    1.4 Market Analysis by Regions

        1.4.1 North America (United States, Canada and Mexico)

            1.4.1.1 United States Market States and Outlook (2013-2023)

            1.4.1.2 Canada Market States and Outlook (2013-2023)

            1.4.1.3 Mexico Market States and Outlook (2013-2023)

        1.4.2 Europe (Germany, France, UK, Russia and Italy)

            1.4.2.1 Germany Market States and Outlook (2013-2023)

            1.4.2.2 France Market States and Outlook (2013-2023)

            1.4.2.3 UK Market States and Outlook (2013-2023)

            1.4.2.4 Russia Market States and Outlook (2013-2023)

            1.4.2.5 Italy Market States and Outlook (2013-2023)

        1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

            1.4.3.1 China Market States and Outlook (2013-2023)

            1.4.3.2 Japan Market States and Outlook (2013-2023)

            1.4.3.3 Korea Market States and Outlook (2013-2023)

            1.4.3.4 India Market States and Outlook (2013-2023)

            1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

        1.4.4 South America, Middle East and Africa

            1.4.4.1 Brazil Market States and Outlook (2013-2023)

            1.4.4.2 Egypt Market States and Outlook (2013-2023)

            1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

            1.4.4.4 South Africa Market States and Outlook (2013-2023)

            1.4.4.5 Nigeria Market States and Outlook (2013-2023)

    1.5 Market Dynamics

        1.5.1 Market Opportunities

        1.5.2 Market Risk

        1.5.3 Market Driving Force

2 Manufacturers Profiles

    2.1 Novartis AG

        2.1.1 Business Overview

        2.1.2 Myelodysplastic Syndrome (MDS) Treatment Type and Applications

            2.1.2.1 Product A

            2.1.2.2 Product B

        2.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.2 Celgene Corporation

        2.2.1 Business Overview

        2.2.2 Myelodysplastic Syndrome (MDS) Treatment Type and Applications

            2.2.2.1 Product A

            2.2.2.2 Product B

        2.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.3 Otsuka Pharmaceutical Co., Ltd

        2.3.1 Business Overview

        2.3.2 Myelodysplastic Syndrome (MDS) Treatment Type and Applications

            2.3.2.1 Product A

            2.3.2.2 Product B

        2.3.3 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.4 Sandoz Inc

        2.4.1 Business Overview

        2.4.2 Myelodysplastic Syndrome (MDS) Treatment Type and Applications

            2.4.2.1 Product A

            2.4.2.2 Product B

        2.4.3 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.5 Dr Reddys Laboratories Limited

        2.5.1 Business Overview

        2.5.2 Myelodysplastic Syndrome (MDS) Treatment Type and Applications

            2.5.2.1 Product A

            2.5.2.2 Product B

        2.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.6 Pharmascience Inc

        2.6.1 Business Overview

        2.6.2 Myelodysplastic Syndrome (MDS) Treatment Type and Applications

            2.6.2.1 Product A

            2.6.2.2 Product B

        2.6.3 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.7 Accord Healthcare Ltd

        2.7.1 Business Overview

        2.7.2 Myelodysplastic Syndrome (MDS) Treatment Type and Applications

            2.7.2.1 Product A

            2.7.2.2 Product B

        2.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.8 Mylan N.V.

        2.8.1 Business Overview

        2.8.2 Myelodysplastic Syndrome (MDS) Treatment Type and Applications

            2.8.2.1 Product A

            2.8.2.2 Product B

        2.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

    3.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Manufacturer (2016-2017)

    3.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Manufacturer (2016-2017)

    3.3 Market Concentration Rate

        3.3.1 Top 3 Myelodysplastic Syndrome (MDS) Treatment Manufacturer Market Share in 2017

        3.3.2 Top 6 Myelodysplastic Syndrome (MDS) Treatment Manufacturer Market Share in 2017

    3.4 Market Competition Trend

4 Global Myelodysplastic Syndrome (MDS) Treatment Market Analysis by Regions

    4.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Regions

        4.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Regions (2013-2018)

        4.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Regions (2013-2018)

    4.2 North America Myelodysplastic Syndrome (MDS) Treatment  Sales and Growth Rate (2013-2018)

    4.3 Europe Myelodysplastic Syndrome (MDS) Treatment  Sales and Growth Rate (2013-2018)

    4.4 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment  Sales and Growth Rate (2013-2018)

    4.5 South America Myelodysplastic Syndrome (MDS) Treatment  Sales and Growth Rate (2013-2018)

    4.6 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment  Sales and Growth Rate (2013-2018)

5 North America Myelodysplastic Syndrome (MDS) Treatment by Countries

    5.1 North America Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Countries

        5.1.1 North America Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Countries (2013-2018)

        5.1.2 North America Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Countries (2013-2018)

    5.2 United States Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

    5.3 Canada Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

    5.4 Mexico Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

6 Europe Myelodysplastic Syndrome (MDS) Treatment by Countries

    6.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Countries

        6.1.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Countries (2013-2018)

        6.1.2 Europe Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Countries (2013-2018)

    6.2 Germany Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

    6.3 UK Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

    6.4 France Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

    6.5 Russia Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

    6.6 Italy Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

7 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment by Countries

    7.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Countries

        7.1.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Countries (2013-2018)

        7.1.2 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Countries (2013-2018)

    7.2 China Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

    7.3 Japan Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

    7.4 Korea Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

    7.5 India Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

    7.6 Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

8 South America Myelodysplastic Syndrome (MDS) Treatment by Countries

    8.1 South America Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Countries

        8.1.1 South America Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Countries (2013-2018)

        8.1.2 South America Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Countries (2013-2018)

    8.2 Brazil Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

    8.3 Argentina Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

    8.4 Colombia Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

9 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment by Countries

    9.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Countries

        9.1.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Countries (2013-2018)

        9.1.2 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Countries (2013-2018)

    9.2 Saudi Arabia Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

    9.3 UAE Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

    9.4 Egypt Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

    9.5 Nigeria Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

    9.6 South Africa Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

10 Global Myelodysplastic Syndrome (MDS) Treatment Market Segment by Type

    10.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Type (2013-2018)

        10.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Type (2013-2018)

        10.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Type (2013-2018)

    10.2 Azacitidine Sales Growth and Price

        10.2.1 Global Azacitidine Sales Growth (2013-2018)

        10.2.2 Global Azacitidine Price (2013-2018)

    10.3 Lenalidomide Sales Growth and Price

        10.3.1 Global Lenalidomide Sales Growth (2013-2018)

        10.3.2 Global Lenalidomide Price (2013-2018)

    10.4 Decitabine Sales Growth and Price

        10.4.1 Global Decitabine Sales Growth (2013-2018)

        10.4.2 Global Decitabine Price (2013-2018)

    10.5 Deferasirox Sales Growth and Price

        10.5.1 Global Deferasirox Sales Growth (2013-2018)

        10.5.2 Global Deferasirox Price (2013-2018)

11 Global Myelodysplastic Syndrome (MDS) Treatment Market Segment by Application

    11.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2013-2018)

    11.2 Refractory cytopenia with unilineage dysplasia Sales Growth (2013-2018)

    11.3 Refractory anemia with ringed sideroblasts Sales Growth (2013-2018)

    11.4 Others Sales Growth (2013-2018)

12 Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)

    12.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Growth Rate (2018-2023)

    12.2 Myelodysplastic Syndrome (MDS) Treatment Market Forecast by Regions (2018-2023)

        12.2.1 North America Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)

        12.2.2 Europe Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)

        12.2.3 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)

        12.2.4 South America Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)

        12.2.5 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)

    12.3 Myelodysplastic Syndrome (MDS) Treatment Market Forecast by Type (2018-2023)

        12.3.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Type (2018-2023)

        12.3.2 Global Myelodysplastic Syndrome (MDS) Treatment Market Share Forecast by Type (2018-2023)

    12.4 Myelodysplastic Syndrome (MDS) Treatment Market Forecast by Application (2018-2023)

        12.4.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Application (2018-2023)

        12.4.2 Global Myelodysplastic Syndrome (MDS) Treatment Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

    13.1 Sales Channel

        13.1.1 Direct Marketing

        13.1.2 Indirect Marketing

        13.1.3 Marketing Channel Future Trend

    13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

    15.1 Methodology

    15.2 Data Source


                        
            

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)3480 View Pricing